Onconic Therapeutics FY 2025 Annual ReportBeta
Onconic Therapeutics annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 13, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Onconic Therapeutics FY 2025 Annual Report Analysis
Business Overview
- • Small molecule drug company focused on acid-related diseases and synthetic lethality oncology, generating 100% revenue from pharmaceuticals
- • Zastaprazan (P-CAB) launched Oct 1, 2024, approved as Korea’s 37th domestic new drug with additional gastric ulcer indication approval in Jun 2025
Management Discussion & Analysis
- • Revenue KRW 53.39B (+259.8% YoY); Operating profit KRW 12.62B (turnaround from -KRW 4.80B); Net income KRW 15.78B (turnaround from -KRW 8.09B)
- • Profit increase driven by milestone payments and contract revenues; management notes pipeline entering Phase 2 clinical trials raising R&D costs
Risk Factors
- • KRW 47.0B cash and cash equivalents at fiscal year-end 2025
- • Net debt KRW -47.0B (net cash position), no borrowings reported at FY2025-end
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding